According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Several other equities analysts have also recently weighed in on NBRV. HC Wainwright started coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They set a buy rating and a $16.00 price objective on the stock. Leerink Swann restated an outperform rating and set a $14.00 price objective on shares of Nabriva Therapeutics AG in a research note on Thursday, October 27th. Finally, Wedbush restated an outperform rating and set a $17.00 price objective on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Nabriva Therapeutics AG currently has an average rating of Buy and an average target price of $13.15.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 4.08 on Tuesday. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $10.69.
Large investors have recently made changes to their positions in the stock. Opaleye Management Inc. raised its stake in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares in the last quarter. Jackson Park Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG during the second quarter valued at about $195,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Nabriva Therapeutics AG during the third quarter valued at about $2,468,000. 63.09% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Nabriva Therapeutics AG (NBRV) Downgraded by Zacks Investment Research to Hold” was posted by Mideast Time and is owned by of Mideast Time. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be accessed at http://www.mideasttime.com/nabriva-therapeutics-ag-nbrv-downgraded-by-zacks-investment-research-to-hold/1418038.html. <p
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.